JP2009137975A5 - - Google Patents

Download PDF

Info

Publication number
JP2009137975A5
JP2009137975A5 JP2008327022A JP2008327022A JP2009137975A5 JP 2009137975 A5 JP2009137975 A5 JP 2009137975A5 JP 2008327022 A JP2008327022 A JP 2008327022A JP 2008327022 A JP2008327022 A JP 2008327022A JP 2009137975 A5 JP2009137975 A5 JP 2009137975A5
Authority
JP
Japan
Prior art keywords
methylerythromycin
solvate
solvent
tetrahydrofuran
carbomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008327022A
Other languages
English (en)
Japanese (ja)
Other versions
JP5190350B2 (ja
JP2009137975A (ja
Filing date
Publication date
Priority claimed from US08/785,623 external-priority patent/US5945405A/en
Application filed filed Critical
Publication of JP2009137975A publication Critical patent/JP2009137975A/ja
Publication of JP2009137975A5 publication Critical patent/JP2009137975A5/ja
Application granted granted Critical
Publication of JP5190350B2 publication Critical patent/JP5190350B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008327022A 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態0 Expired - Lifetime JP5190350B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/785,623 1997-01-17
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003311358A Division JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0

Publications (3)

Publication Number Publication Date
JP2009137975A JP2009137975A (ja) 2009-06-25
JP2009137975A5 true JP2009137975A5 (OSRAM) 2011-10-13
JP5190350B2 JP5190350B2 (ja) 2013-04-24

Family

ID=25136084

Family Applications (3)

Application Number Title Priority Date Filing Date
JP53437298A Expired - Lifetime JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態0
JP2003311358A Withdrawn JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0
JP2008327022A Expired - Lifetime JP5190350B2 (ja) 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態0

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP53437298A Expired - Lifetime JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態0
JP2003311358A Withdrawn JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0

Country Status (18)

Country Link
US (1) US5945405A (OSRAM)
EP (1) EP1077988A1 (OSRAM)
JP (3) JP4058114B2 (OSRAM)
KR (1) KR100567149B1 (OSRAM)
CN (1) CN1174991C (OSRAM)
AR (3) AR011077A1 (OSRAM)
AU (1) AU735598B2 (OSRAM)
BR (1) BR9714287A (OSRAM)
CA (4) CA2387356C (OSRAM)
CZ (1) CZ297433B6 (OSRAM)
DE (1) DE97951771T1 (OSRAM)
ES (1) ES2173058T1 (OSRAM)
IL (1) IL130255A0 (OSRAM)
NZ (1) NZ336073A (OSRAM)
TR (1) TR199901578T2 (OSRAM)
TW (1) TW574224B (OSRAM)
WO (1) WO1998031699A1 (OSRAM)
ZA (1) ZA98116B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2578701A (en) 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
CN1193036C (zh) * 2000-03-15 2005-03-16 韩美药品工业株式会社 制备甲红霉素-克拉霉素ⅱ型晶体的方法
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
EP1411899B1 (en) * 2001-08-01 2009-03-11 Novartis AG Taste masking composition
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシンa誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンa誘導体の製造方法
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンa誘導体およびその製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンaオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
PT915899E (pt) * 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Similar Documents

Publication Publication Date Title
JP2004075689A5 (OSRAM)
CN1297564C (zh) 4″-取代-9-脱氧-9a-氮杂-9a-高红霉素A衍生物的制备方法
AU2015342444B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
DE97951771T1 (de) Kristall-form 0 von clarithromycin
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
CN1259955A (zh) C-4"-取代的大环内酯衍生物
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
CN107501369B (zh) 一种胞苷衍生物的制备方法及其应用
US10807978B2 (en) Process for preparation of palbociclib
WO2016107289A1 (zh) 制备索非布韦晶型6的方法
WO2018000250A1 (zh) 依鲁替尼新晶型及其制备方法
JP2022060192A5 (OSRAM)
CN101277694B (zh) 盐酸伊立替康的新晶形
CN1178951C (zh) 新型红霉素衍生物,其制法及其作为药物的应用
CN1351607A (zh) 大环内酯抗生素的新晶形
JP2020524707A (ja) 塩酸メフパリブの多形体およびその製造方法と使用
CN105367558B (zh) 穿心莲内酯衍生物及其制备方法和用途
TWI656116B (zh) Crystal form of 9-aminomethyl substituted tetracycline compound and preparation method thereof
AU2014352372A1 (en) Taxane compound, and preparation method and use thereof
JP6533794B2 (ja) タキサン化合物、その調製方法およびその使用
US8349863B2 (en) Crystalline polymorphic form of a camptothecin analogue
CN112225730B (zh) 一种稠环化合物的晶型、其组合物、制备方法及其应用
WO2019037591A1 (zh) 盐酸美法仑晶型及其制备方法与应用
CN1798755A (zh) O-烷基大环内酯和氮杂内酯衍生物和制备这些化合物的区域选择性方法
CN116710101A (zh) A-失碳-5α雄甾烷化合物的多晶型物